Researchers from the Johns Hopkins Bloomberg School of Public Health supported the first blood center in the U.S. to be granted full FDA approval to provide convalescent plasma to immunocompromised ...

Convalescent plasma was one of the first treatments created at the start of the pandemic in an attempt to help the seriously ill. But the WHO now says evidence shows convalescent plasma doesn't ...

Convalescent plasma – a once-celebrated treatment for COVID-19 that has largely fallen out of favor – does work well for people who are immune-compromised, according to a study published Thursday.The ...

Convalescent plasma may be another tool to help prevent coronavirus infections sparked by the omicron variant from turning severe if patients receive it soon after developing symptoms, according to ...

Guidance for industry on the use of convalescent plasma for patients with COVID-19 has been updated to reflect the 23 August Emergency Use Authorization (EUA) for the investigational product. The ...

One potential treatment for COVID-19, known as convalescent plasma, may be derived from patients who have already recovered from the disease, and the US Food and Drug Administration (FDA) said Tuesday ...

Joyner is a professor in the Department of Anesthesiology and Perioperative Medicine at the Mayo Clinic and led the U.S. Expanded Access Program for Convalescent Plasma. Wright is a professor of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Convalescent plasma, when administered within 9 days of ...

Johns Hopkins Medicine researchers report that a prospective study of 14 infants and children demonstrated that convalescent plasma—a blood product collected from patients recovered from infections ...